Hopp til hovedinnhold

Stevens-Johnson syndrom og toksisk epidermal nekrolyse

Sist revidert:
Sist revidert av:

Definisjon:
Akutt, livstruende hudsykdom som viser seg ved utbredt erytrodermi, løsning av epidermis og mukosa ledsaget av feber og varierende grad av organinvolvering - oftest legemiddelindusert.
Forekomst:
Insidensen, inklusive Stevens-Johnson syndrom, angis å være ca. 4-7 tilfeller per 1 million innbyggere per år.
Symptomer:
Begynner ofte med prodromer i form av feber og influensalignende symptomer, og ubehag i slimhinner og øyne.
Funn:
Etter 1-3 dager kommer et utslett i ansiktet, på halsen og de sentrale deler av kroppen med et rødt og meslingeliknende utslett som raskt brer seg utover ekstremitetene, og som fører til blemmedannelse og flekkvis løsning av huden.
Diagnostikk:
Klinisk diagnose. Hudstansebiopsi kan bekrefte diagnosen.
Behandling:
Seponering av utløsende medikament og generell intensivbehandling.
  1. Bygum A, Andersen KE. Toksisk epidermal nekrolyse. Ugeskr Læger 2006; 168: 2645-9. PubMed  
  2. High WA. Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis. UpToDate, last updated Mar 12, 2019. UpToDate  
  3. Cohen V. Toxic epidermal necrolysis. Medscape, last updated Dec 20, 2018. emedicine.medscape.com  
  4. Letko E, Papaliodis DN, Papaliodis GN et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94: 419-36. PubMed  
  5. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343. pmid:19029983 PubMed  
  6. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155: 722. pmid:16965421 PubMed  
  7. Kridin K, Brüggen M-C, Chua S-L, et al. Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Insights From a Pan-European Multicenter Study. JAMA Dermatol 2021; 157: 1182-90. pmid:34431984 PubMed  
  8. de Prost N, Ingen-Housz-Oro S, Duong Ta, et al. Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010; 89:28. PubMed  
  9. Morales ME, Purdue GF, Verity SM, et al. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. Am J Ophthalmol 2010; 150:505. PubMed  
  10. de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 2014; 42:118. PubMed  
  11. Jha AK, Goenka MK. Colonic involvement in Stevens-Johnson syndrome: a rare entity. Dig Endosc 2012; 24:382. PubMed  
  12. Chave TA, Mortimer NJ, Sladden MJ et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-53. PubMed  
  13. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013; 133:1197. PubMed  
  14. High WA. Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae. UpToDate, last updated Sep 27, 2021. UpToDate  
  15. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 2012; 167: 424-32. PubMed  
  16. Zárate-Correa LC, Carrillo-Gómez DC, Ramírez-Escobar AF, Serrano-Reyes C. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol 2013; 23:61. PubMed  
  17. Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol 2014; 71:278. PubMed  
  • Terje Johannessen, professor i allmennmedisin, Trondheim